Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
admin 13th July 2017 Uncategorised 0AstraZeneca’s Lynparza is defending its lead in ovarian cancer against new head-to-head rivals from Tesaro and Clovis Oncology. But as the PARP inhibitor medications rack up various FDA approvals, U.S. cost watchdog ICER has drawn some conclusions about the class—mostly that they’re too expensive.
More: Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Source: fierce